📊 CBIO Key Takeaways
Is Crescent Biopharma, Inc.. (CBIO) a Good Investment?
Crescent BioPharma is a pre-revenue biotech company with severe operational losses and negative cash flow despite having substantial cash reserves. The company is burning capital at an unsustainable rate with operating expenses far exceeding minimal revenue, indicating immature or failed drug development programs with no clear path to profitability.
Crescent Biopharma has a very strong balance sheet, with $213.19M of cash, no meaningful debt, and solid liquidity, which provides substantial near-term operating flexibility. However, the business remains deeply unprofitable, with very large operating and free cash flow losses, and the revenue jump does not yet translate into durable earnings quality. Fundamentally, this looks like a well-funded but still highly speculative biotech profile where cash runway and execution matter more than current income statement strength.
Why Buy Crescent Biopharma, Inc.. Stock? CBIO Key Strengths
- Strong liquidity position with $213.2M in cash and 6.56x current ratio, providing runway for operations
- Minimal debt burden with 0.00x debt-to-equity ratio, reducing financial distress risk
- Substantial equity cushion of $203.0M providing balance sheet stability
- Very strong liquidity, with cash representing the large majority of total assets and current and quick ratios at 6.56x
- Debt-free capital structure reduces financial risk and gives management flexibility to fund development
- Net loss improved year over year and revenue increased sharply, indicating some operational progress or milestone-related inflows
CBIO Stock Risks: Crescent Biopharma, Inc.. Investment Risks
- Massive operating losses of -$152.6M with -1407.5% operating margin indicating failed or delayed drug development
- Severe negative cash flow of -$72.5M free cash flow annually will deplete cash reserves in ~3 years at current burn rate
- Near-zero revenue of $10.8M with no gross profit metrics suggests no viable commercial products or market traction
- Negative ROE of -75.8% and ROA of -64.1% demonstrate value destruction and inefficient capital deployment
- No insider buying activity in 90 days suggests lack of management confidence
- Profitability remains extremely weak, with operating margin of -1407.5% and net margin of -1419.6%
- Free cash flow is deeply negative at -$72.45M, implying continued dependence on existing cash reserves or future capital raises
- Revenue quality is uncertain because a sharp spike in a biotech can be non-recurring and is not yet supported by sustainable earnings power
Key Metrics to Watch
- Operating cash flow trend and runway remaining with current burn rate
- Revenue growth and pipeline advancement of drug candidates toward commercialization
- Operating expense management and path to operational profitability
- Cash position and potential need for dilutive financing
- Clinical trial progress and regulatory milestones for lead programs
- Quarterly operating cash burn relative to cash balance
- Revenue durability and trend in operating loss as programs advance
Crescent Biopharma, Inc.. (CBIO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.56x current ratio provides a solid financial cushion.
CBIO Profit Margin, ROE & Profitability Analysis
CBIO vs Healthcare Sector: How Crescent Biopharma, Inc.. Compares
How Crescent Biopharma, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Crescent Biopharma, Inc.. Stock Overvalued? CBIO Valuation Analysis 2026
Based on fundamental analysis, Crescent Biopharma, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Crescent Biopharma, Inc.. Balance Sheet: CBIO Debt, Cash & Liquidity
CBIO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Crescent Biopharma, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.58 indicates the company is currently unprofitable.
CBIO Revenue Growth, EPS Growth & YoY Performance
CBIO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $75.0K | -$8.3M | $-0.14 |
| Q2 2023 | $75.0K | -$8.3M | $-0.13 |
| Q3 2022 | $75.0K | -$8.5M | $-0.16 |
| Q2 2022 | $142 | -$13.3M | $-0.25 |
| Q1 2022 | $1.1M | -$14.3M | $-0.28 |
| Q3 2021 | $86.6K | -$7.7M | N/A |
| Q2 2021 | $142 | -$7.7M | N/A |
| Q1 2021 | $1.1M | -$7.7M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Crescent Biopharma, Inc.. Dividends, Buybacks & Capital Allocation
CBIO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Crescent Biopharma, Inc.. (CIK: 0001253689)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CBIO
What is the AI rating for CBIO?
Crescent Biopharma, Inc.. (CBIO) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (HOLD) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CBIO's key strengths?
Claude: Strong liquidity position with $213.2M in cash and 6.56x current ratio, providing runway for operations. Minimal debt burden with 0.00x debt-to-equity ratio, reducing financial distress risk. ChatGPT: Very strong liquidity, with cash representing the large majority of total assets and current and quick ratios at 6.56x. Debt-free capital structure reduces financial risk and gives management flexibility to fund development.
What are the risks of investing in CBIO?
Claude: Massive operating losses of -$152.6M with -1407.5% operating margin indicating failed or delayed drug development. Severe negative cash flow of -$72.5M free cash flow annually will deplete cash reserves in ~3 years at current burn rate. ChatGPT: Profitability remains extremely weak, with operating margin of -1407.5% and net margin of -1419.6%. Free cash flow is deeply negative at -$72.45M, implying continued dependence on existing cash reserves or future capital raises.
What is CBIO's revenue and growth?
Crescent Biopharma, Inc.. reported revenue of $10.8M.
Does CBIO pay dividends?
Crescent Biopharma, Inc.. does not currently pay dividends.
Where can I find CBIO SEC filings?
Official SEC filings for Crescent Biopharma, Inc.. (CIK: 0001253689) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CBIO's EPS?
Crescent Biopharma, Inc.. has a diluted EPS of $-0.59.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CBIO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Crescent Biopharma, Inc.. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CBIO stock overvalued or undervalued?
Valuation metrics for CBIO: ROE of -75.8% (sector avg: 15%), net margin of -1,419.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CBIO stock in 2026?
Our dual AI analysis gives Crescent Biopharma, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CBIO's free cash flow?
Crescent Biopharma, Inc..'s operating cash flow is $-71.5M, with capital expenditures of $919.0K. FCF margin is -668.1%.
How does CBIO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,419.6% (avg: 12%), ROE -75.8% (avg: 15%), current ratio 6.56 (avg: 2).